» Articles » PMID: 29156792

Liquid Biopsy in Colon Cancer: Comparison of Different Circulating DNA Extraction Systems Following Absolute Quantification of Mutations Using Intplex Allele-specific PCR

Overview
Journal Oncotarget
Specialty Oncology
Date 2017 Nov 22
PMID 29156792
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Non-invasive molecular analysis of circulating tumor DNA (ctDNA) is a promising application in personalized cancer management, although there is still much to learn about the biological characteristics of ctDNA. The present study compared absolute amounts of mutated ctDNA and total circulating cell-free DNA (cfDNA) in colorectal cancer (CRC) patients (n=50) from various stages and healthy controls (n=8) by Intplex allele-specific and digital droplet PCR. In addition, the impact of two prominent extraction techniques (silica-based membrane vs. magnetic beads) on cfDNA and ctDNA recovery was analyzed in 38 paired samples from CRC patients and specific spike-in DNA controls. CfDNA fragment size was assessed using the Agilent 2100 Bioanalyzer. Relative quantities of total cfDNA quantities were measured using the Qubit fluorometer. Statistical analysis on total cfDNA yield revealed a strong correlation (r=0.976) between Qubit and absolute Intplex allele-specific PCR measurements in cancer patients and healthy controls. Total cfDNA was significantly increased in cancer patients compared to healthy controls, with the highest yield in distant metastatic disease. In line, the highest amount of ctDNA (1.35 ng/μL) was found in patients with distant organ metastasis. Of great interest, the silica-based membrane method significantly promoted extraction of long cfDNA fragments. In contrast, the magnetic bead system more efficiently recovered short cfDNA fragments in serum of cancer patients. Further, a decreased allele frequency was observed in serum compared to plasma. This study suggests that the source of cfDNA and choice of pre-analytical extraction systems needs to be more carefully validated in routine clinical practice.

Citing Articles

Extracted Plasma Cell-Free DNA Concentrations Are Elevated in Colic Patients with Systemic Inflammation.

Bayless R, Cooper B, Sheats M Vet Sci. 2024; 11(9).

PMID: 39330806 PMC: 11435807. DOI: 10.3390/vetsci11090427.


Large language model produces high accurate diagnosis of cancer from end-motif profiles of cell-free DNA.

Liu J, Shen H, Chen K, Li X Brief Bioinform. 2024; 25(5).

PMID: 39222060 PMC: 11367762. DOI: 10.1093/bib/bbae430.


Investigation of Extracted Plasma Cell-Free DNA as a Biomarker in Foals with Sepsis.

Hobbs K, Cooper B, Dembek K, Sheats M Vet Sci. 2024; 11(8).

PMID: 39195800 PMC: 11359113. DOI: 10.3390/vetsci11080346.


Exploring RAS mutation incidence and temporal heterogeneity in metastatic colorectal cancer patients - a single-institution experience utilising circulating tumour DNA.

Zarkavelis G, Amylidi A, Torounidou N, Yerolatsite M, Keravasili A, Keramisanou V Contemp Oncol (Pozn). 2024; 28(1):45-50.

PMID: 38800532 PMC: 11117156. DOI: 10.5114/wo.2024.138899.


Clinical Practice Guideline for Blood-based Circulating Tumor DNA Assays.

Lee J, Cho E, Kim B, Hong J, Kim Y, Kim Y Ann Lab Med. 2024; 44(3):195-209.

PMID: 38221747 PMC: 10813828. DOI: 10.3343/alm.2023.0389.


References
1.
Thress K, Brant R, Carr T, Dearden S, Jenkins S, Brown H . EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer. 2015; 90(3):509-15. DOI: 10.1016/j.lungcan.2015.10.004. View

2.
Oshiro C, Kagara N, Naoi Y, Shimoda M, Shimomura A, Maruyama N . PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients. Breast Cancer Res Treat. 2015; 150(2):299-307. DOI: 10.1007/s10549-015-3322-6. View

3.
Sherwood J, Corcoran C, Brown H, Sharpe A, Musilova M, Kohlmann A . Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC). PLoS One. 2016; 11(2):e0150197. PMC: 4769175. DOI: 10.1371/journal.pone.0150197. View

4.
Mouliere F, El Messaoudi S, Gongora C, Guedj A, Robert B, Del Rio M . Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load. Transl Oncol. 2013; 6(3):319-28. PMC: 3660801. DOI: 10.1593/tlo.12445. View

5.
Bettegowda C, Sausen M, Leary R, Kinde I, Wang Y, Agrawal N . Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6(224):224ra24. PMC: 4017867. DOI: 10.1126/scitranslmed.3007094. View